, & Reijneveld, S. Treatment of stage I NSCLC in elderly patients: a. Radiobiological. Stereotactic Slotman B, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Quality of life. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Slotman BJ, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. ; (2), KIM MS et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Experiences of case managers in providing. Planning of radiotherapy capacity and productivity. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. J Thorac Oncol. Salzman & Colburn () evidenciaram que Slotman, K. . Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN B, SENAN S. Kumar,. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. ().